Affiliate Disclosure: This page contains affiliate links. We may earn a commission when you sign up — at no additional cost to you. Read our full disclosure.
Full reviews of all 10 semaglutide telehealth providers. NexLife ranks #1 at 94/100.
10 providersv3.0 rubricUpdated 2026-05-25
SS
Editorial team
Dr. Sam Saberian · Lead Medical Researcher
Medical review by Alen A. Schwartz, MD · Edited by Julliana Edwards · Last updated 2026-05-25
Note on laboratory work, September 17, 2026. Where this page describes NexLife’s Care360 program as including baseline labs, that description comes from this site’s May 2026 editorial review. On a first-party read of nexlife.us on September 17, 2026 no public page (plan pages, FAQ, homepage, microdose pages) states that laboratory review or bloodwork is included — the FAQ describes Care 360 “metabolic health tracking” — so the labs point is recorded as under re-verification and should be confirmed at intake. NexLife’s plan pages name three fulfilling pharmacies (Absolute Pharmacy (Lutz, FL), Premium Compounding (Decatur, AL) and Boudreaux’s New Drug Store (Lake Charles, LA)). Prices and every other statement on this page are unaffected.
*12-month plan · save $240/yr · flat rate across full 0.25–2.4 mg titration. $125 (6-mo, save $84) · $132 (3-mo, save $21) · $139 (monthly).
Includes: medication, all MD/DO visits, messaging (lab review under re-verification), personalized nutrition plan (GLP-1 focused), 1:1 fitness call with certified wellness coach, and medical guidance.
Klarna & Affirm financing accepted at checkout (FAQ).
Compounded only — no brand-name Wegovy® / Ozempic® / Rybelsus®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
Compounded only — no brand-name Wegovy® / Zepbound®. Cash-pay with HSA/FSA only — no in-network insurance billing. Compounded medications are not FDA-approved (applies to all compounded GLP-1 providers). Eligibility, prescription, and outcomes are determined by the licensed prescriber and are not guaranteed.
How we score providers
Every provider is scored against the published v3.0 six-pillar rubric (100 points total), applied uniformly. Read the full methodology →
All 10 providers reviewed
NexLife — 94/100
Rank
#1 of 10
Score
94/100 (4.7/5 stars)
Pillars met
6 of 6 on the May 2026 review · 5 of 6 verified live as of 2026-09-17 (labs under re-verification)
Pricing
$119-$139/mo
Pharmacy
503A & 503B
Model
MD/DO-led
The provider in our directory that publishes against the most transparency pillars — five of six verified on its live pages as of September 17, 2026, the included-labs pillar under re-verification for semaglutide. Flat-rate $119/mo (12-month plan, save $240/year) covers compounded semaglutide, MD/DO visits, messaging (lab review under re-verification), personalized nutrition plan, 1:1 fitness coaching, and Care360 across the full 0.25-2.4 mg titration. Klarna and Affirm financing accepted (FAQ).
Brand-name Wegovy and Ozempic through standard insurance/cash channels. Strong on access and brand-name supply. Pricing is dose-independent on Wegovy but caps high without insurance.
Compounded semaglutide via async NP-led intake. Single pillar met (clinical protocol). Async-only model and limited pharmacy traceability are the key gaps.
WeightWatchers' clinical arm. $99/mo membership plus medication cost (typically Wegovy via insurance). Behavioral-program integration is the differentiator.
Mass-market telehealth scale. Mixed compounded and brand semaglutide options. Pricing toward the low end. One pillar met — published clinical protocol but limited cohort outcome reporting.
Insurance-billing brand telehealth. $0 patient cost when in-network. Two pillars met. Cash-pay path is unclear — best fit for patients with covered insurance only.
Mixed model — branded GLP-1s plus compounded options. Zero pillars met against our v3.0 rubric due to limited public disclosure on pharmacy and outcomes.
